Allergan up on good migraine drug trials and financial results

Ireland-incorporated drugmaker Allergan (NYSE: AGN) was up 2% premarket on light volume in response to its announcement of positive results from a Phase III clinical trial, ACHIEVE I, evaluating ubrogepant in adult patients experiencing a single migraine attack. Both co-primary endpoints were met.

The ACHIEVE I study included 1,327 US adult patients (modified ITT population) randomized (1:1:1) to placebo, ubrogepant 50mg and 100mg respectively, who were treated for a single migraine attack of moderate to severe headache intensity. Both doses showed a statistically-significant greater percentage of ubrogepant patients achieving pain freedom at 2 hours after the initial dose as compared to placebo patients (50mg vs placebo, p=0.0023, 100mg vs placebo, p=0.0003) and a statistically-significant greater percentage of ubrogepant patients achieving absence of the most bothersome migraine-associated symptom at 2 hours after the initial dose as compared to placebo patients (50mg vs placebo, p=0.0023, 100mg vs placebo, p=0.0023).

Additional results from this study are anticipated to be released at upcoming scientific meetings throughout 2018.